Abstract
Eupatilin is a flavonoid compound isolated from the Artemisia plant. Eupitillin possesses antioxidant as well as potent anticancer properties. In this study, for the first time, we examined the anti-proliferative effects of Eupatilin in human melanoma A375 cells and its ability to induce apoptosis and cell cycle arrest. Eupatilin specifically induced morphological changes in A375 cells and was less toxic to the normal mouse splenocytes. The inhibitory effects of A375 cells were associated with the DNA damage, apoptosis, and cell cycle arrest at G2/M phase in a dose-dependent manner. The apoptotic effects of Eupatilin were further verified by using Annexin V-FITC/propidium iodide staining in flow cytometry. These results suggest that Eupatilin is an effective natural compound that worth further mechanistic and therapeutic studies against human melanoma. Key words: Eupatilin, melanoma, apoptosis, cell cycle arrest.
Highlights
Melanoma, a malignant and aggressive tumor has continuously increasing incidence all over the world
Choi et al (2009) has reported the novel antitumor, cytotoxic activity of Eupatilin through robust induction of apoptosis in human gastric carcinoma AGS cells complementing the previous findings by Kim at al. (2005b) and Lee et al (2008)
DMEM culture medium, Methylthiazolyldiphenyltetrazolium MTT, Propidium iodide (PI), Hoechst, Trypan blue dye, and Dimethyl sulfoxide (DMSO) were purchased from Sigma.Annexin-V FITC apoptosis detection kit was purchased from Beyotime Institute of Biotechnology Jiangsu China
Summary
A malignant and aggressive tumor has continuously increasing incidence all over the world. In this study, for the first time we have evaluated the activity of Eupatilin on human melanoma cell line A375. The growth inhibitory effect of the Eupatilin on the viability of cells was determined by the MTT assay. The percentages of cells in the different phases of cell cycle were evaluated by determining the DNA content after propidium iodide staining.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.